To date, two oral antiviral agents have been approved in Aotearoa New Zealand for treating COVID-19 in adults who are at increased risk of progressing to severe disease, hospitalisation or death. This article reports on the uptake of these medicines between April 2022 and December 2023, based on dispensing data provided by Te Whatu Ora.